

FDA-Authorized Oral Medications

for Treatment of COVID-19 in *Non-Hospitalized* Patients

Oral antiviral medications are FDA authorized for COVID-19. These medications work by interfering with the ability of the COVID-19 virus to replicate inside the body. This lowers the “viral load,” which is the amount of virus doctors find in your body. This can help reduce the severity of COVID-19 symptoms and shorten the length of the illness.

This table is for informational purposes only. Treatments require a prescription and should be guided by a patient's healthcare team.

Paxlovid¹ (nirmatrelvir and ritonavir tablets)

Important note: Paxlovid may impair the efficacy and safety of certain cancer medications. It should be used with the guidance of your oncologist

Authorized for	Treatment of mild-to-moderate COVID-19 confirmed by a positive COVID-19 test in <u>non-hospitalized patients</u> who are at high risk of progression to severe infection (such as blood cancer patients and survivors) Paxlovid treatment is not <ul style="list-style-type: none"> • For use in preventing COVID-19 infection • Authorized for use longer than 5 consecutive days
Ages	Adults 18 years and older Children 12 and up who weigh at least 88 pounds
Activity against Omicron	Effective against the Omicron variant in preliminary laboratory studies and likely to be effective in patients ^{2,3}
Dosing/Timing	<ul style="list-style-type: none"> • Treatment should begin as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset • Three tablets (2 nirmatrelvir and 1 ritonavir) taken together twice daily for 5 days • Can be taken with or without food
Manufacturer	Pfizer Click here to read the manufacturer's Fact Sheet for Patients, Parents and Caregivers.

Lagevrio⁴ (molnupiravir)

Authorized for	Treatment of mild-to-moderate COVID-19 confirmed by a positive COVID-19 test in non-hospitalized patients who are at high risk of progression to severe infection (such as blood cancer patients and survivors) Lagevrio treatment is not <ul style="list-style-type: none"> • For use in preventing COVID-19 infection • Authorized for use longer than 5 consecutive days
Ages	Adults 18 years and older
Activity against Omicron	Effective against the Omicron variant in preliminary laboratory studies and likely to be effective in patients ^{2,3}
Dosing/Timing	<ul style="list-style-type: none"> • Treatment should begin as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset • Four capsules taken every 12 hours for 5 days • Can be taken with or without food
Manufacturer	Merck & Co., Inc. Click here to read the manufacturer's Fact Sheet for Patients, Parents and Caregivers.

1. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid; 2. Dabrowska A et al. Efficacy of antiviral drugs against the omicron variant of SARS-CoV-2. 3. Vangeel L et al. Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 omicron and other variants of concern. 4. Fact sheet for Healthcare Providers: Emergency Use Authorization for Molnupiravir